- Home
- QUIK vs ANL Comparison
QUIK vs ANL Comparison
Compare QUIK & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUIK
- ANL
- Stock Information
- Founded
- QUIK 1988
- ANL 2004
- Country
- QUIK United States
- ANL Cayman Islands
- Employees
- QUIK N/A
- ANL N/A
- Industry
- QUIK Semiconductors
- ANL
- Sector
- QUIK Technology
- ANL
- Exchange
- QUIK Nasdaq
- ANL Nasdaq
- Market Cap
- QUIK 87.3M
- ANL 73.8M
- IPO Year
- QUIK 1997
- ANL 2023
- Fundamental
- Price
- QUIK $5.89
- ANL $1.47
- Analyst Decision
- QUIK Strong Buy
- ANL Buy
- Analyst Count
- QUIK 3
- ANL 2
- Target Price
- QUIK $10.87
- ANL N/A
- AVG Volume (30 Days)
- QUIK 133.0K
- ANL 14.7K
- Earning Date
- QUIK 08-12-2025
- ANL 08-08-2025
- Dividend Yield
- QUIK N/A
- ANL N/A
- EPS Growth
- QUIK N/A
- ANL N/A
- EPS
- QUIK N/A
- ANL N/A
- Revenue
- QUIK $18,768,000.00
- ANL N/A
- Revenue This Year
- QUIK $11.58
- ANL N/A
- Revenue Next Year
- QUIK $40.23
- ANL N/A
- P/E Ratio
- QUIK N/A
- ANL N/A
- Revenue Growth
- QUIK N/A
- ANL N/A
- 52 Week Low
- QUIK $4.26
- ANL $1.10
- 52 Week High
- QUIK $13.36
- ANL $4.10
- Technical
- Relative Strength Index (RSI)
- QUIK 54.14
- ANL 37.32
- Support Level
- QUIK $5.66
- ANL $1.56
- Resistance Level
- QUIK $6.06
- ANL $1.74
- Average True Range (ATR)
- QUIK 0.31
- ANL 0.15
- MACD
- QUIK 0.02
- ANL -0.01
- Stochastic Oscillator
- QUIK 50.29
- ANL 12.50
About QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.